Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1586/erc.10.83 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Dronedarone for the treatment of atrial fibrillation: a NICE single technology appraisal.
Pharmacoeconomics
January 2012
Centre for Health Economics, University of York, York, UK.
The National Institute for Health and Clinical Excellence (NICE) invited the manufacturer of dronedarone (Multaq®, Sanofi-Aventis Limited, UK) to submit evidence on the clinical and cost effectiveness of the anti-arrhythmic drug (AAD) for the treatment of atrial fibrillation (AF) and atrial flutter, as part of the Institute's single technology appraisal (STA) process. The Centre for Reviews and Dissemination and the Centre for Health Economics, both at the University of York, were commissioned to act as the independent Evidence Review Group (ERG). This article provides a description of the company submission, the ERG review and NICE's subsequent decisions regarding the use of dronedarone within the UK NHS.
View Article and Find Full Text PDFDronedarone for the treatment of atrial fibrillation and atrial flutter.
Health Technol Assess
October 2010
Centre for Reviews and Dissemination/Centre for Health Economics, University of York, York, UK.
This paper presents a summary of the evidence review group (ERG) report on the clinical effectiveness and cost-effectiveness of dronedarone for the treatment of atrial fibrillation (AF) or atrial flutter based upon a review of the manufacturer's submission to the National Institute for Health and Clinical Excellence (NICE) as part of the single technology appraisal process. The population considered in the submission were adult clinically stable patients with a recent history of or current non-permanent AF. Comparators were the current available anti-arrhythmic drugs: class 1c agents (flecainide and propafenone), sotalol and amiodarone.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!